ASC42 – Patient Worthy

source: pixabay.com

The First Patient has Been Dosed in a Clinical Trial for Primary Biliary Cholangitis Treatment

Post author:Trudy Horsting
Post published:May 30, 2022
Post category:Primary Biliary Cholangitis

Gannex has just announced that they have dosed the first patient in their Phase 2 clinical trial examining ASC42 as a treatment for those diagnosed with primary biliary cholangitis (PBC).…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

The First Patient has Been Dosed in a Clinical Trial for Primary Biliary Cholangitis Treatment

Why Your Voice in Research Matters: Groundbreaking Studies are Changing What's Possible

Rethinking What It Means to Live With Acromegaly

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

Let’s Work Together!

Keep Up to Date

Learn More